Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 10/20 | 0.33 |
| ▸ | PPARD | Q03181 | 9/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966435 | 0.89 | FFAR1 (0.41) | PPARAPPARDFFAR1 | |
| SCHEMBL3965811 | 0.86 | CYP11B1 (0.40) | CYP11B1CYP11B2PPARAPPARDHSD17B1 | |
| SCHEMBL3968890 | 0.82 | CYP11B1 (0.38) | CYP11B1CYP11B2PPARAHSD17B1PPARG | |
| SCHEMBL3965573 | 0.76 | POLB (0.41) | CYP11B1CYP11B2PPARDHSD17B1 | |
| SCHEMBL3966733 | 0.74 | PPARD (0.48) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL3969570 | 0.71 | PPARD (0.52) | PPARAPPARDHSD17B1FFAR1 | |
| SCHEMBL3967329 | 0.71 | CYP11B1 (0.44) | CYP11B1CYP11B2PPARAPPARDHSD17B1 | |
| SCHEMBL3967925 | 0.71 | POLB (0.41) | CYP11B1CYP11B2HSD17B1 | |
| SCHEMBL3966953 | 0.71 | PPARD (0.44) | CYP11B1CYP11B2PPARAPPARDPPARG | |
| SCHEMBL3969607 | 0.70 | CYP11B1 (0.41) | CYP11B1CYP11B2PPARAPPARDHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | CYP11B1 44/4885CYP11B2 47/4885CA12 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.